Translation and psychometric properties of the Arabic version of the revised Patients' Attitudes Towards Deprescribing questionnaire

Abstract Objectives This study aims to validate an Arabic version of the revised Patients' Attitudes Toward Deprescribing (rPATD) translated tool and to describe polypharmacy patients' attitudes toward deprescribing in Jordan. Methods rPATD translation was guided by ISPOR’s Principles of Good Practice. A convenient sample of adult outpatients with polypharmacy was recruited from a major teaching hospital in Jordan. Reliability was assessed using Cronbach's alpha and the intraclass correlation coefficient (ICC). Validity was assessed using face and construct validity using confirmatory factor analysis. Key findings A total of 358 questionnaires were collected from patients (mean age: 60.4 ± 12.03). Overall, polypharmacy patients were willing to stop one or more of their medications upon a physician's recommendations and were not concerned about deprescribing. Similar to the original rPATD tool, factor analysis resulted in four factors (burden, appropriateness, concern about stopping, and involvement). Internal consistencies for constructs ranged from 0.718 (appropriateness) to 0.85 (concerns about stopping). ICC ranged from 0.718–0.972, indicating good to excellent reliability. Conclusions This study provided an Arabic translation of the rPATD with evidence of validity and reliability comparable to the original tool. The Arabic rPATD could be used for adult patients in Arabic‐speaking countries to ultimately contribute to the global literature of deprescribing. Overall, the patients in this study showed a favourable attitude towards deprescribing through a shared decision‐making process with their physicians. This can be seen as an opportunity to reduce the burden of polypharmacy and unnecessary medications..

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:11

Enthalten in:

Journal of pharmaceutical health services research - 11(2020), 2, Seite 173-181

Beteiligte Personen:

Nusair, Mohammad B. [VerfasserIn]
Arabyat, Rasha [VerfasserIn]
Al‐Azzam, Sayer [VerfasserIn]
El‐Hajji, Feras Darwish [VerfasserIn]
Nusir, Amal T. [VerfasserIn]
Al‐Batineh, Mohammed [VerfasserIn]

BKL:

44.40

Anmerkungen:

JPHSR © 2020 Royal Pharmaceutical Society

Umfang:

9

doi:

10.1111/jphs.12340

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

WLY009375120